{"name":"Ripple Therapeutics Pty Ltd","slug":"ripple-therapeutics-pty-ltd","ticker":"","exchange":"","domain":"","description":"Ripple Therapeutics Pty Ltd is a biotechnology company focused on developing innovative treatments for unmet medical needs. The company's pipeline includes two drug candidates, both in Phase 2 clinical trials, targeting specific therapeutic areas.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"IBE-814 70ug","genericName":"IBE-814 70ug","slug":"ibe-814-70ug","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"IBE-814 70ug","genericName":"IBE-814 70ug","slug":"ibe-814-70ug","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxOTlQzRkpQQlZDZXVlTFU3RzJWVV9HN3RhdWxyQ1gxdGJDaHFvZWpFQy1tOWRDbXhESDk2RkVWajdQZ2NhSTFncGlxTF9WTEVXMTdYZlhWdmd6NVI3b1FTbGdCZjNGTXBrVWp3S19GUF9DZlh0OFF3RXI0cU1XMFZhVXFzZjJZVkNpUU95bm9Jc0Y3Sm9yMkFoQ1dTTzNPb29PY0MwZ2VWaXJNR3d0WHgtY1BXV0FFWlMzZFRwdGl6VmR5U2xGMUNSLTRLdm9UQ2p6dVlvYU1BemYySTVLTE5va3ZFdmxvb0thRXNUNzlCVWJld0VuUDZn?oc=5","date":"2025-09-09","type":"pipeline","source":"PR Newswire","summary":"Open-Angle Glaucoma Market Outlook Brightens as Emerging Therapies Reshape Treatment Paradigms | DelveInsight - PR Newswire","headline":"Open-Angle Glaucoma Market Outlook Brightens as Emerging Therapies Reshape Treatment Paradigms | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxQMHhfSGI1a3NjMkNsRC1ZdkRNUzJnS0FnMkhZbFBiRWF2Ykp0cHlVQ3IyZVRsZWNQQjNEaW5ESUd5V0ktU3NYYnI4NHAxT0tDLVFQZ0dDMlhyekNqZzI4RnRhX3FXV3VnX1VFODIwMkRvdUwxMEJqRlBjNnkwRktlODhwSEJOWEVVaERzXzlPTGdpSDNITmpFWXdjYldwUHkwWXVldjZXSkp6N3lZWC1LOEtqOGJRY05NdU52V1JFejhKX1BFS3NXRG1wd0NnckxyNmdIRWxoUGVnalJOeWp3Rl9TaDNHYThTOHc?oc=5","date":"2025-03-25","type":"pipeline","source":"PR Newswire","summary":"ROCKLATAN/ROCLANDA Strengthens Market Position with Robust Sales and Patient Outcomes | DelveInsight - PR Newswire","headline":"ROCKLATAN/ROCLANDA Strengthens Market Position with Robust Sales and Patient Outcomes | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwJBVV95cUxONzJwRzBpN1dGQ1h1QkRLdEFDQnRrcTJhMUkwSTJRdk9uZWJkVUZOd2VNel8tTWlJYzZkSzdJSG9nRXRuZFpkVFpEV1RKMDBvTWlkNnRaN3BzVUU5SWdZZDVwc1djWWhEaVhPRjlxWS15RDRJbm9hS29hQllqQktObGtUTDZ6OHlRQ2F4ZGlNQzFRUlpNakd2MkdiU244N3hLX3lka3FHS3VoTlVtbzJ2LXk2UHJ0ckZ5VjdGUi1MSUFRaU5YX2kxb2tOUnJoUFItM256NTFaaHhRSlpFRjdNVWE1eEZmY3RzdW5LZmZGcmI4dEVaNFlWcmZFQ3RXRVhfaGctMVhYTm9pdVMyaUx4ZC1feDh1SGk2czRLRUJzaDQydWVlWUdQUFR6bzJ5c09PaUtCWFNoQQ?oc=5","date":"2025-02-26","type":"pipeline","source":"GlobeNewswire","summary":"DURYSTA’s Market Potential Across the 7MM is Set to Soar - GlobeNewswire","headline":"DURYSTA’s Market Potential Across the 7MM is Set to Soar","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwJBVV95cUxQeHhISHVyb2Z5d2h0aGoyZW4takJhLTlQaDlYbFFlaTRvMnBrN3h6cEttemhWelM0SzRkRFlzVlkzTkdET1dqb2xZcVdjZ0pKWGZIVnd0QnBDRHJjN0J3WXZmaWRpU0g4VndCYk9zSE94dF80VWNWX01MYXpJci02SFozdHlOdlR2TkM0ckNpdjBzVHE5U2hVUzc0U0dMODBXZkNYY08xOFh1OE53eWRRYi03cUIwQlh3d0JvTU41djhNMm9Mc3hBelZldmRETjlQd3ptNmlkY2RuQm9zR1F4WlMzeVQyUnhxeDdBSUNSbjRJX1NLVjI0ZEs0bmY3dWh4dDd1TFZKbjlpNTlIeXdqdm9PWG1mS3hEMTNTTmRjZw?oc=5","date":"2025-01-20","type":"trial","source":"GlobeNewswire","summary":"Advancements in Ocular Hypertension Clinical Trial Pipeline - GlobeNewswire","headline":"Advancements in Ocular Hypertension Clinical Trial Pipeline","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}